HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $51
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Genmab (NASDAQ:GMAB) and raises the price target from $47 to $51.
May 22, 2023 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Genmab and raises the price target from $47 to $51.
The news of HC Wainwright & Co. maintaining a Buy rating and raising the price target for Genmab is positive for the company's stock. This indicates that the analyst believes the stock has potential for growth and is likely to perform well in the short term. As a result, the stock price may go up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100